Navigation Links
Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment

NEW YORK, June 13, 2007--Three new drugs for rheumatoid arthritis (RA) have ushered in a new era of treatment for this difficult and debilitating condition. The findings are reported in a New Drug Class study published early Online and in an upcoming edition of The Lancet.

RA is the most common of all chronic inflammatory joint diseases, affecting 0·5–1% of the population in the industrialised world. Its typical symptoms are joint pain, stiffness, and swelling due to synovial inflammation and effusion.

Professor Josef Smolen, Division of Rheumatology, Medical University of Vienna, Austria and colleagues did a comprehensive study of the three new drugs—rituximab, abatacept and tocilizumab—and their effects as sole therapies or working in conjunction with existing treatments. They explore the pathogenesis of RA and the various routes for targeting treatments, including new therapeutic strategies, and also provide a comprehensive overview on ways to assess treatment response.

The authors say: "The enormous consequences of RA for the individual and for health-care and socioeconomic systems can only be prevented by effective treatments."

Traditional treatments for RA include non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs). Only DMARDs, and to some extent glucocorticoids, can impede or stop the inflammatory and destructive disease processes. Methotrexate is the most widely used DMARD and is a cornerstone of most RA treatment regimens.

Of the three new drugs, rituximab and abatacept have been approved for RA treatment, while the third, tocilizumab, is in phase III trials. Rituximab targets the CD20 antigen in certain cells, and leads to a reduction in the CD20 cell count. Trials of rituximab showed it reduced RA symptoms by more than 50% for more tha
'"/>




Page: 1 2 3

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
4. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
5. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
6. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
9. Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Three New Drugs Mark New Era Rheumatoid Arthritis Treatment
(Date:1/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) has ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - ... has been the topic of fascination since the era of ... and the Soviet Russia. Earlier even a small glimpse ...
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... 2015  Pete Rose, baseball,s all-time hits leader, is the new ... Myoflex, Ducere Pharma has announced. "Pete,s a Hall ... have him on board with Myoflex," said Ducere Pharma Chief ... player who is known across all generations. The passion and ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... VION PHARMACEUTICALS,INC. (Nasdaq: VION ) today ... trial of its lead anticancer agent Cloretazine(R),(VNP40101M) in ... acute myelogenous leukemia (AML) and high-risk,myelodysplastic syndromes (MDS). ... Ellen K. Ritchie, M.D. at The Weill-Cornell Medical ...
... May Provide New Option for Clinicians Concerned About ... Systemic Exposure When Using an ... Inc. (NYSE: ALO ),a leading global specialty pharmaceutical ... week at the American Pain Society annual,meeting demonstrate the ...
Cached Medicine Technology:Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... Asch, MD, MBA, the Robert D. Eilers Professor of Medicine ... Pennsylvania School of Medicine and the Wharton School, was presented ... Award by the Association American of Medical Colleges (AAMC). ... association,s annual meeting in Boston. Recognizing Dr. ...
... recovery may actually prevent happiness, researchers say , TUESDAY, Nov. ... the hope that they will get better may actually lead ... important part of happiness, but there,s a dark side of ... with their life, it can get in the way of ...
... ... ... 2009 -- Entest BioMedical, Inc. (OTCBB: ENTB) discussed its current therapies in development ... and their potential to generate significant revenue for the Company., , ,1.   Immuno-therapeutic treatment of ...
... LOS ANGELES, Nov. 10 Research conducted by the Center ... on the effects of a popular form of hyperbaric oxygen ... The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with ... at 1.3 atmospheres of pressure, does not have a significant ...
... ... concern for many Americans and when the future of health is very ... the United States. Consumers now have more options to consider when making ... than now. Easy Pha-max provides superior quality plant-based nutritional products that can ...
... ... expanding its cutting edge vibration exercise technology into South America, beginning in Argentina, Chile ... and Contour Plus, are now available in South America. , ... (Vocus) November 10, 2009 -- WAVE (Whole-Body ...
Cached Medicine News:Health News:David A. Asch, M.D., M.B.A., receives AAMC Distinguished Teacher Award 2Health News:Acceptance of Chronic Illness Helps People Move On 2Health News:Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company 2Health News:Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company 3Health News:Center for Autism and Related Disorders Study Finds Hyperbaric Oxygen Therapy Ineffective Treatment for Children with Autism 2Health News:Major Biotechnology Franchise Company Expands Rapidly Throughout the USA Amidst Mounting Health Concerns 2Health News:WAVE's Revolutionary Whole-Body Advanced Vibration Exercise Is Now Available in South America 2
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
West lacrimal cannula, blunt tip, 0.3 mm side opening....
Lacrimal cannula, malleable tip, straight....
The first easy-to use peroxide system offers proven efficacy that's pure and simple. The convenience of a multi-purpose cleaner/rinse in one bottle. Added power of peroxide in the other bottle....
Medicine Products: